WO2013036015A3 - 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 - Google Patents

아제티딘 유도체 및 이를 함유하는 항우울제 조성물 Download PDF

Info

Publication number
WO2013036015A3
WO2013036015A3 PCT/KR2012/007076 KR2012007076W WO2013036015A3 WO 2013036015 A3 WO2013036015 A3 WO 2013036015A3 KR 2012007076 W KR2012007076 W KR 2012007076W WO 2013036015 A3 WO2013036015 A3 WO 2013036015A3
Authority
WO
WIPO (PCT)
Prior art keywords
azetidine derivative
composition containing
containing same
antidepressant composition
antidepressant
Prior art date
Application number
PCT/KR2012/007076
Other languages
English (en)
French (fr)
Other versions
WO2013036015A2 (ko
Inventor
한호규
남기달
한민수
한영휘
송치만
신동윤
Original Assignee
한국과학기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국과학기술연구원 filed Critical 한국과학기술연구원
Priority to EP12829591.2A priority Critical patent/EP2754653B1/en
Priority to US14/239,890 priority patent/US9120771B2/en
Publication of WO2013036015A2 publication Critical patent/WO2013036015A2/ko
Publication of WO2013036015A3 publication Critical patent/WO2013036015A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

아제티딘 유도체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 항우울제 또는 정신질환 예방 또는 치료용 조성물이 제공된다. 상기 아제티딘 유도체는 신경전달물질인 도파민, 세레토닌, 노에피네프린의 재흡수를 동시에 억제할 수 있는 삼중 흡수 억제제(triple reuptake inhibitor)로서 유용하다.
PCT/KR2012/007076 2011-09-05 2012-09-04 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 WO2013036015A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP12829591.2A EP2754653B1 (en) 2011-09-05 2012-09-04 Azetidine derivative and antidepressant composition containing same
US14/239,890 US9120771B2 (en) 2011-09-05 2012-09-04 Azetidine derivative and antidepressant composition including the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110089820A KR101273566B1 (ko) 2011-09-05 2011-09-05 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
KR10-2011-0089820 2011-09-05

Publications (2)

Publication Number Publication Date
WO2013036015A2 WO2013036015A2 (ko) 2013-03-14
WO2013036015A3 true WO2013036015A3 (ko) 2013-05-02

Family

ID=47832694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007076 WO2013036015A2 (ko) 2011-09-05 2012-09-04 아제티딘 유도체 및 이를 함유하는 항우울제 조성물

Country Status (4)

Country Link
US (1) US9120771B2 (ko)
EP (1) EP2754653B1 (ko)
KR (1) KR101273566B1 (ko)
WO (1) WO2013036015A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101651994B1 (ko) * 2014-01-29 2016-08-30 한국과학기술연구원 아릴옥시 아제티딘 화합물, 및 이를 포함하는 약학 조성물
CN107646031B (zh) * 2015-05-20 2020-11-17 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物
CN109963834B (zh) 2016-11-18 2023-04-14 综合研究实验室瑞典股份公司 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
EP4159725A4 (en) 2020-05-29 2023-12-20 Daegu-Gyeongbuk Medical Innovation Foundation CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF MENTAL DISEASES
CN116057053A (zh) 2020-05-29 2023-05-02 大邱庆北尖端医疗产业振兴财团 含至少一个n的5元杂芳基衍生物和含其为活性成分用于预防或治疗精神障碍的药物组合物
US20230212121A1 (en) 2020-05-29 2023-07-06 Daegu-Gyeongbuk Medical Innovation Foundation Sulfonamide derivative and pharmaceutical composition comprising same as active ingredient for preventing or treating mental illness

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028961A2 (en) * 2004-09-03 2006-03-16 Athersys, Inc. Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
WO2009109743A1 (en) * 2008-03-04 2009-09-11 Vernalis (R&D) Ltd. Azetidine derivatives
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83230C2 (ru) * 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
EP1718609A1 (en) 2004-02-17 2006-11-08 Laboratorios Del Dr. Esteve, S.A. Substituted azetidine compounds, their preparation and use as medicaments
BRPI0813837A2 (pt) * 2007-07-27 2015-01-06 Hoffmann La Roche 2-azetidinametanoaminas e 2-pirrolidinametanoaminas como ligantes de taar
US8575364B2 (en) * 2008-10-30 2013-11-05 Janssen Pharmaceutica Nv Modulators of serotonin receptor
WO2010059393A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Serotonin receptor modulators
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028961A2 (en) * 2004-09-03 2006-03-16 Athersys, Inc. Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
WO2009109743A1 (en) * 2008-03-04 2009-09-11 Vernalis (R&D) Ltd. Azetidine derivatives
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALESCIO. T.: "Effect of a proline analogue, azetidine-2-carboxylic acid, on the morphogenesis in vitro of mouse embryonic lung", J. EMBRYOL. EXP. MORPH., vol. 29, no. 2, 1973, pages 439 - 451, XP055143150 *
FELEDZIAK ET AL.: "SAR and LC/MS Studies of beta-Lactamic Inhibitors of Human Fatty Acid Amide Hydrolase (hFAAH): Evidence of a Nonhydrolytic Process", J. MED. CHEM., vol. 54, no. 19, 8 September 2011 (2011-09-08), pages 6812 - 6823, XP055143153 *
HAN, YOUNGHUE ET AL.: "Exploration of Novel 3‑Substituted Azetidine Derivatives As Triple Reuptake Inhibitors", J. MED. CHEM., vol. 55, 31 August 2012 (2012-08-31), pages 8188 - 8192, XP055143159 *
See also references of EP2754653A4 *

Also Published As

Publication number Publication date
KR20130026292A (ko) 2013-03-13
EP2754653A2 (en) 2014-07-16
EP2754653B1 (en) 2016-11-09
US9120771B2 (en) 2015-09-01
US20140171402A1 (en) 2014-06-19
KR101273566B1 (ko) 2013-06-11
EP2754653A4 (en) 2015-02-18
WO2013036015A2 (ko) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013036015A3 (ko) 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
GEP20207129B (en) Inhibitors of influenza viruses replication
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
IN2014KN00948A (ko)
WO2010110545A3 (ko) 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
WO2006057950A3 (en) 4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
MY151211A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
WO2012103226A3 (en) Bendamustine formulations
EA017249B8 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
SA517390552B1 (ar) مركبات بلورية مثبط امتصاص ثلاثي غير متوازن
WO2009118765A3 (en) Novel monoamine re-uptake inhibitor
WO2012118308A3 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
WO2011008666A3 (en) 3-phenoxymethylpyrrolidine compounds
HK1185878A1 (zh) 用於治療或預防由血清素、去甲腎上腺素或多巴胺的神經傳遞的減少而引起的疾病的雜環化合物
WO2010117979A3 (en) Serotonin and norepinephrine reuptake inhibitor
WO2012173382A3 (ko) 탄시논ⅱａ를 유효성분으로 함유하는 피부 외용제 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829591

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14239890

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2012829591

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012829591

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE